Is There an Association Between Serum Neurofilament Light Chain Levels and Conduction Slowing in Type 2 Diabetic Distal Symmetrial Polyneuropathy? (P3-4.003)

Authors

Joseph Wardell
Kelly Saverino
Belinda Philip
Kazim Jaffry
Ankit Pahwa
Daniel Menkes, Corewell Health
Zhao Zhong Chong
Nizar Souayah

Document Type

Conference Proceeding

Publication Date

4-9-2024

Publication Title

Neurology

Abstract

Objective:

To investigate the association between serum NEFL levels and conduction slowing in diabetic DSP.

Background:

The neurofilament light chain (NEFL) is a blood biomarker of neuroaxonal damage in several neurodegenerative diseases and is a potential biomarker for type 2 diabetic distal symmetrical polyneuropathy (DSP).

Design/Methods:

Serum concentration of NEFL was measured in 8 patients with diabetic DSP with motor conduction slowing (MCVS) and was compared to 10 patients with diabetic DSP without motor conduction slowing (MCVWS) and 7 normal controls.

Results:

The Overall Neuropathy Limitations Scale (ONLS), Rasch-Built Overall Disability Scale (R-ODS), and Total Neuropathy Score were 4.16 ± 2.19, 36.28 ± 11.64, and 16.67 ± 8.35 respectively in MCVS group compared to 3.70 ± 1.55, 16.6 ± 5.8, and 36.00 ± 6.44 in MCVWS group respectively. The level of HBA1C was significantly higher in the MCVS group (7.90 ± 2.04%) compared to the MCVWS group (5.51 ± 0.82%). Serum concentration of NEFL was significantly increased in the MCVS group (286.64 ± 98.50 pg/ml) compared to MCVWS (248.90 ± 142.91, P<0.05) and normal control group (107.87 ± 76.14 pg/ml, P<0.01).

Conclusions:

Our preliminary data demonstrated that conduction slowing in diabetic DSP is associated with poor diabetic control and increased serum NEFL suggestive of ongoing axonal loss. Work in progress to investigate if there is a correlation between NEFL and the severity of conduction slowing (suggestive of primary demyelination with secondary axonal loss), as well as with other biomarkers of neuroinflammation.

Volume

102

Issue

17 Suppl 1

Comments

American Academy of Neurology Annual Meeting, AAN 2024, April 13-18, 2024, Denver, CO

Recommended Citation

Wardell J, Saverino K, Philip B, Jaffry K, Pahwa A, Menkes D, et al. Is there an association between serum neurofilament light chain levels and conduction slowing in type 2 diabetic distal symmetrical polyneuropathy? (P3-4.003). doi:10.1212/WNL.0000000000204938

DOI

10.1212/WNL.0000000000204938